Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03158129. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
Study identification
- NCT ID
- NCT03158129
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 101 participants
Conditions and interventions
Conditions
- Stage I Lung Non-Small Cell Cancer AJCC v7
- Stage IA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7
- Stage II Lung Non-Small Cell Cancer AJCC v7
- Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Docetaxel Drug
- Ipilimumab Biological
- Nivolumab Biological
- Pemetrexed Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 15, 2017
- Primary completion
- Nov 12, 2024
- Completion
- Nov 12, 2024
- Last update posted
- Apr 5, 2026
2017 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03158129, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03158129 live on ClinicalTrials.gov.